Myriad Genetics, AstraZeneca, Merck expand collaboration, using BRACAnalysis CDx to identify germline BRCA in men with mCRPC cancer

Myriad Genetics, AstraZeneca, and Merck have expanded their companion diagnostic collaboration, to use BRACAnalysis CDx to identify germline BRCA mutations in men who have metastatic castrate-resistant prostate (mCRPC) cancer and are enrolled in the Phase III PROfound study.

Myriad said that, if the study succeeds, it will file a ask the FDAto have BRACAnalysis CDx as a companion diagnostic to Lynparza (olaparib) for its use in this patient population.

The collaboration between Myriad and AstraZeneca on Lynparza began in 2007 and has resulted in multiple regulatory approvals for BRACAnalysis CDx. 

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.